By STEVE MITCHELL
UPI Senior Medical Correspondent
WASHINGTON, July 5 (UPI) -- Tibotec's HIV drug, TMC125, may be better at fighting resistant strains of the virus than current medications, according to two phase 3 trials released Thursday. Read more here
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment